New Therapies on the Horizon for Elderly or Frail Patients With Head and Neck Cancer
A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population.
Diagnosis & Disease Information
Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
Liquid Biopsy-Guided Therapy Improves Survival in Lung Cancer
Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.
Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
Antibody-Drug Conjugate Proves Active in Advanced, Resistant EGFR-Mutated Lung Cancer
Responses were observed across EGFR TKI resistance mechanisms.
Durvalumab Improves Survival When Added to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.
Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women
Data showed increases in endometrial cancer and obesity in women younger than 40.
Combination Anlotinib and Sintilimab Exhibits Antitumor Activity in Advanced Endometrial Cancer
Nearly three-quarters of patients responded to treatment.
Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy
The signature was prognostic for locoregional recurrence.
- Loading...
Loading...
Next post in ASCO 2021 Breast Cancer In-depth
Loading... 
Loading...